Malin Corporation

Malin PLC operates as a publicly listed investment company, strategically deploying capital into innovative life sciences enterprises. It primarily focuses on high-potential therapeutic areas such as oncology, immunology, and genetic diseases. The company's core approach involves providing long-term financial backing and substantial operational support to its portfolio firms, aiming to accelerate the development and commercialization of transformative medical treatments.

The company was established in late 2014 by a group of former executives from the Irish drug development firm Elan, notably including Kelly Martin. This founding team leveraged its extensive industry experience and network, recognizing a critical need for patient capital and specialized guidance within the burgeoning life sciences sector. The insight was to create a platform that could support ambitious biotech ventures through their lengthy development cycles.

Malin's client base consists of its diverse portfolio of early-stage and growth-oriented life sciences companies. Its overarching vision is to generate compelling returns for its shareholders by nurturing these businesses to realize their full potential, ultimately delivering groundbreaking therapeutic solutions to patients worldwide. The company is committed to fostering innovation that addresses significant unmet medical needs.